title: Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Charokopou
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: H
authors.initials: H
authors.lastname: Vioix
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: S
authors.initials: S
authors.lastname: Dillon
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: D
authors.initials: D
authors.lastname: Franks